Immunex Corp. (NASDAQ:IMNX) of Seattle announcedWednesday that it has filed a product license amendment tothe FDA to use Leukine for prophylaxis and treatment ofchemotherapy-induced neutropenia, an abnormally low whiteblood cell level.
This white blood cell stimulant is used to speed recovery ofcancer patients undergoing autologous bone marrowtransplantation and to improve survival of cancer patientswhose bone marrow transplants have failed. The expandedlabel application includes data from studies of patients whohave undergone a variety of cancer therapies in whichSargramostim was used to accelerate neutrophil production.
(c) 1997 American Health Consultants. All rights reserved.